Ligand id: 7331

Name: lenalidomide

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 1
Topological polar surface area 95.99
Molecular weight 259.1
XLogP 0.2
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in combination with anti-inflammatory dexamethasone as a second line therapy to treat multiple myeloma and other myelodysplastic syndromes. Lenalidomide is considered an orphan drug as the diseases for which it is indicated are rare.
In February 2015, the US FDA extended approval of the lenalidomide/dexamethasone combination to include use as a first line treatment for patients with newly diagnosed multiple myeloma. In February 2017, the FDA expanded approval for use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Mechanism Of Action and Pharmacodynamic Effects
The precise mechanism of action of this drug has not been fully resolved. Drug action appears to be multi-faceted, exhibiting direct anti-tumor action, anti-angiogenic action, as well as immunomodulatory activity. LIke thalidomide, lenalidomide has been shown to interact with the ubiquitin E3 ligase component, cereblon (CRBM, Q96SW2) [2].
External links